FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

(Reuters) - Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar version of Amgen Inc's drug, Neulasta, to market, with U.S. health regulators approving its version of the blockbuster infection-fighting treatment.

Source: Reuters: Health - June 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news